Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
bit.bio has raised €132M across 2 funding rounds from 8 investors, most recently a round in Jan 2026. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-01-12 | Other | €43M | M&G Investments | View deal → |
| 2021-11-08 | Series B | €89M | Arch Ventures,Charles River Laboratories,Foresite Capital,Metaplanet,Puhua Capital,Resilience+1 more | View deal → |
